ClinicalTrials.gg
Not yet recruitingNCT07075965CAP DM1Updated Nov 9, 2026

Calcium Channel Blocker in Myotonic Dystrophy Type 1

A Phase 1 interventional study of Amlodipine in Myotonic Dystrophy 1, sponsored by University of Rochester. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Rochester · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Funding Source - FDA OOPD

This is a Phase 1 clinical trial designed to evaluate the safety and tolerability of amlodipine, a calcium channel blocker, in adults with Myotonic Dystrophy Type 1 (DM1). Amlodipine is being studied to see if it can improve muscle strength, reduce stiffness (myotonia), and improve function by modifying calcium flow in muscle cells. All participants will receive amlodipine starting at 2.5 mg daily for 2 weeks, then 5 mg for 4 weeks. After that, participants will be randomly assigned to continue on 5 mg or increase to 10 mg for an additional 4 weeks. The main goals are to assess changes in blood pressure and any adverse events to determine whether the drug is safe in this population. The study will also explore how amlodipine affects muscle strength, mobility, fatigue, and daily function using clinical tests and questionnaires. Findings will inform a future phase 2 trial.

02

Conditions studied

  • Myotonic Dystrophy 1

Browse trials for

03

In context

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

This study's planned enrollment of 20 is below the median of 40 across 68 interventional studies indexed under Myotonic Dystrophy.

Browse Myotonic Dystrophy studies →

Lead sponsor

University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female between the ages 18 and 65, inclusive.
  • A genetically confirmed diagnosis of DM1, having a repeat expansion in the DMPK gene with at least 100 CTG repeats.
  • Grip strength less than 50% predicted based on age, height, and sex.
  • Video hand opening time is 4 sec or greater for at least one hand.
  • Ambulatory and able to walk 10 meters.
  • Willingness to discontinue anti-myotonia drugs at least 2 weeks prior to screening.
  • Highly effective method of in women with .

Exclusion criteria

Exclusion Criteria:

  • Congenital DM1 as defined by symptom onset in the first 4 weeks of life.
  • Abnormal liver function tests (LFTs): (ALT), or aspartate aminotransferase (AST) >3 x . Total > 1.5 mg/dL, or > 1.3, or evidence of current active or chronic infection with , or other hepatobiliary conditions other than DM1 (or attributed to DM1) that cause abnormal liver laboratory parameters (e.g., hemochromatosis, Wilson's disease, hepatitis)
  • Current or recent infection requiring antibiotic treatment within 2 weeks prior to screening.
  • Abnormal vital signs, including systolic blood pressure \< 90 mmHg and diastolic blood pressure \< 60 mmHg.
  • Treatment with concomitant medications with potential interactions with amlodipine, these may include but are not limited to sildenafil, cyclosporin, atorvastatin at high dosages (80 mg daily), simvastatin (at dosages higher than 20 mg daily) or strong inhibitors of .
  • A history of syncope.
  • A history of symptomatic hypotension.
  • Initiation or change in doses of concomitant medications, including herbal supplements, if in the opinion of the Investigator, may impact the results of the study.
  • Women of must have a negative pregnancy test, cannot be planning a pregnancy, and cannot be breastfeeding at any time during the study.
  • Known history of substance and/or alcohol abuse within one year prior to screening.
  • The presence of comorbidities that, in the opinion of the Investigator, may influence study results, including, but not limited to, uncontrolled diabetes, generalized or mononeuropathy of the upper extremities, or cervical radiculopathy resulting in weakness and atrophy.
  • Concurrent treatment with calcium channel blocker.
  • Known ischemic or non-ischemic moderate or severe heart failure as defined by symptoms suggestive of heart failure or reduced (LVEF) on echocardiogram \< 55%.
  • Moderate or severe aortic stenosis or other obstruction of the left ventricle outflow tract.
  • Known sensitivity or allergy to amlodipine.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cohort A

    Amlodipine 5 mg

    Drug: Amlodipine

  • Experimental
    Cohort B

    Amlodipine 10 mg

    Drug: Amlodipine

Interventions

  • Evaluating 2 different doses of amlodipine, after an initial titration phase (2.5 mg daily), amlodipine is increased to the target doses of 5 mg and 10 mg

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Provided Informed Consent

    The total number of participants who signed the informed consent document and were enrolled in the study.

    Time frame: Baseline

  2. Number of Completed Study Visits

    The total number of completed study visits, averaged across all enrolled participants. A visit is considered completed if all required procedures for that visit were performed.

    Time frame: Baseline to End of Study at week 10

  3. Number of Subjects Who Completed the Study Without Drug Discontinuation

    Number of participants who completed all study visits and remained on study drug throughout the study period without permanent discontinuation due to adverse events, withdrawal, or protocol deviations.

    Time frame: Baseline to End of Study at week 10

  4. Number of Subjects Who Completed the Study

    Number of participants who completed all required study visits and procedures through the final study visit.

    Time frame: Baseline to End of Study at week 10

Secondary outcomes

  1. Mean Change in Systolic Blood Pressure

    Systolic blood pressure (SBP) will be measured using a standardized automated sphygmomanometer in a seated position after 5 minutes of rest. The mean change will be calculated as the difference between SBP at the final study visit and baseline

    Time frame: Baseline to End of Study at week 10

  2. Number of Participants With Non-Serious Adverse Events

    Number of participants who experienced at least one non-serious adverse event, as determined by investigator assessment and participant report. Events will be recorded according to MedDRA coding guidelines.

    Time frame: Baseline to End of Study at week 10

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Oct 2030, 45 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Jul 20, 2025
StartEst.
Dec 7, 2026
Primary completionEst.
Oct 1, 2030
CompletionEst.
Oct 1, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and description
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07075965
Responsible party
Johanna Hamel (Associate Professor - Department of Neurology, NMD (SMD), University of Rochester) — Principal investigator
First posted
Jul 20, 2025
Start date
Dec 7, 2026 (estimated)
Primary completion
Oct 1, 2030 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Jeanne M Dekdebrun, MS
Contact
Jeanne_Dekdebrun@URMC.Rochester.edu
585-276-4611

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion